BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 19877646)

  • 1. Hypoxia-activated prodrugs: substituent effects on the properties of nitro seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (nitroCBI) prodrugs of DNA minor groove alkylating agents.
    Tercel M; Atwell GJ; Yang S; Stevenson RJ; Botting KJ; Boyd M; Smith E; Anderson RF; Denny WA; Wilson WR; Pruijn FB
    J Med Chem; 2009 Nov; 52(22):7258-72. PubMed ID: 19877646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoxic selectivity and solubility--investigating the properties of A-ring substituted nitro seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-ones (nitroCBIs) as hypoxia-activated prodrugs for antitumor therapy.
    Tercel M; Yang S; Atwell GJ; Smith E; Gu Y; Anderson RF; Denny WA; Wilson WR; Pruijn FB
    Bioorg Med Chem; 2010 Jul; 18(14):4997-5006. PubMed ID: 20580559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of a bromide leaving group on the properties of nitro analogs of the duocarmycins as hypoxia-activated prodrugs and phosphate pre-prodrugs for antitumor therapy.
    Stevenson RJ; Denny WA; Ashoorzadeh A; Pruijn FB; van Leeuwen WF; Tercel M
    Bioorg Med Chem; 2011 Oct; 19(20):5989-98. PubMed ID: 21920763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of sulfonate leaving groups on the hypoxia-selective toxicity of nitro analogs of the duocarmycins.
    Ashoorzadeh A; Atwell GJ; Pruijn FB; Wilson WR; Tercel M; Denny WA; Stevenson RJ
    Bioorg Med Chem; 2011 Aug; 19(16):4851-60. PubMed ID: 21767954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitro seco analogues of the duocarmycins containing sulfonate leaving groups as hypoxia-activated prodrugs for cancer therapy.
    Stevenson RJ; Denny WA; Tercel M; Pruijn FB; Ashoorzadeh A
    J Med Chem; 2012 Mar; 55(6):2780-802. PubMed ID: 22339090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy.
    Hay MP; Anderson RF; Ferry DM; Wilson WR; Denny WA
    J Med Chem; 2003 Dec; 46(25):5533-45. PubMed ID: 14640560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase.
    Hay MP; Atwell GJ; Wilson WR; Pullen SM; Denny WA
    J Med Chem; 2003 Jun; 46(12):2456-66. PubMed ID: 12773049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-Amino-1-(chloromethyl)-1,2-dihydro-3H-benz[e]indoles: relationships between structure and cytotoxicity for analogues bearing different DNA minor groove binding subunits.
    Atwell GJ; Milbank JJ; Wilson WR; Hogg A; Denny WA
    J Med Chem; 1999 Aug; 42(17):3400-11. PubMed ID: 10464026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of 1-substituted 3-(chloromethyl)-6-aminoindoline (6-amino-seco-CI) DNA minor groove alkylating agents and structure-activity relationships for their cytotoxicity.
    Milbank JB; Tercel M; Atwell GJ; Wilson WR; Hogg A; Denny WA
    J Med Chem; 1999 Feb; 42(4):649-58. PubMed ID: 10052972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unsymmetrical DNA cross-linking agents: combination of the CBI and PBD pharmacophores.
    Tercel M; Stribbling SM; Sheppard H; Siim BG; Wu K; Pullen SM; Botting KJ; Wilson WR; Denny WA
    J Med Chem; 2003 May; 46(11):2132-51. PubMed ID: 12747786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and evaluation of stable bidentate transition metal complexes of 1-(chloromethyl)-5-hydroxy-3-(5,6,7-trimethoxyindol-2-ylcarbonyl)-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline (seco-6-azaCBI-TMI) as hypoxia selective cytotoxins.
    Milbank JB; Stevenson RJ; Ware DC; Chang JY; Tercel M; Ahn GO; Wilson WR; Denny WA
    J Med Chem; 2009 Nov; 52(21):6822-34. PubMed ID: 19821576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.
    Wilson WR; Hicks KO; Pullen SM; Ferry DM; Helsby NA; Patterson AV
    Radiat Res; 2007 Jun; 167(6):625-36. PubMed ID: 17523848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine N3 DNA minor groove alkylators.
    Wilson WR; Stribbling SM; Pruijn FB; Syddall SP; Patterson AV; Liyanage HD; Smith E; Botting KJ; Tercel M
    Mol Cancer Ther; 2009 Oct; 8(10):2903-13. PubMed ID: 19808982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and structure-activity relationships for 2,4-dinitrobenzamide-5-mustards as prodrugs for the Escherichia coli nfsB nitroreductase in gene therapy.
    Atwell GJ; Yang S; Pruijn FB; Pullen SM; Hogg A; Patterson AV; Wilson WR; Denny WA
    J Med Chem; 2007 Mar; 50(6):1197-212. PubMed ID: 17326614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylator.
    Ahn GO; Botting KJ; Patterson AV; Ware DC; Tercel M; Wilson WR
    Biochem Pharmacol; 2006 Jun; 71(12):1683-94. PubMed ID: 16620789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of antibody conjugates of phosphate prodrugs of cytotoxic DNA alkylators for the targeted treatment of cancer.
    Zhao RY; Erickson HK; Leece BA; Reid EE; Goldmacher VS; Lambert JM; Chari RV
    J Med Chem; 2012 Jan; 55(2):766-82. PubMed ID: 22148292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and anti-cancer activity of 2,6-disubstituted N-methylpiperidine derivatives and their N-oxides.
    Henderson ND; Plumb JA; Robins DJ; Workman P
    Anticancer Drug Des; 1996 Sep; 11(6):421-38. PubMed ID: 8836108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity.
    Singleton RS; Guise CP; Ferry DM; Pullen SM; Dorie MJ; Brown JM; Patterson AV; Wilson WR
    Cancer Res; 2009 May; 69(9):3884-91. PubMed ID: 19366798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia-selective antitumor agents. 12. Nitrobenzyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine.
    Tercel M; Wilson WR; Anderson RF; Denny WA
    J Med Chem; 1996 Mar; 39(5):1084-94. PubMed ID: 8676343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia-selective antitumor agents. 13. Effects of acridine substitution on the hypoxia-selective cytotoxicity and metabolic reduction of the bis-bioreductive agent nitracrine N-oxide.
    Lee HH; Wilson WR; Ferry DM; van Zijl P; Pullen SM; Denny WA
    J Med Chem; 1996 Jun; 39(13):2508-17. PubMed ID: 8691448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.